Glycoprotein 41 (gp41) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Glycoprotein 41 (gp41) - Pipeline Review, H2 2016

Glycoprotein 41 (gp41) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Glycoprotein 41 (gp41) - Pipeline Review, H2 2016
Published Oct 12, 2016
73 pages — Published Oct 12, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Glycoprotein 41 (gp41) - Pipeline Review, H2 2016, provides in depth analysis on Glycoprotein 41 (gp41) targeted pipeline therapeutics.

The report provides comprehensive information on the Glycoprotein 41 (gp41), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Glycoprotein 41 (gp41) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Glycoprotein 41 (gp41)
- The report reviews Glycoprotein 41 (gp41) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Glycoprotein 41 (gp41) targeted therapeutics and enlists all their major and minor projects
- The report assesses Glycoprotein 41 (gp41) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Glycoprotein 41 (gp41) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Glycoprotein 41 (gp41)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mer

  
Source:
Document ID
GMDHC0583TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents25
  List of Tables51
  List of Figures61
Introduction71
  Global Markets Direct Report Coverage71
Glycoprotein 41 (gp41) Overview81
Therapeutics Development93
  Glycoprotein 41 (gp41) Products under Development by Stage of Development91
  Glycoprotein 41 (gp41) Products under Development by Therapy Area101
  Glycoprotein 41 (gp41) Products under Development by Indication111
Glycoprotein 41 (gp41) Pipeline Products Glance122
  Late Stage Products121
  Early Stage Products131
Glycoprotein 41 (gp41) Products under Development by Companies142
Glycoprotein 41 (gp41) Products under Development by Universities/Institutes162
Glycoprotein 41 (gp41) Therapeutics Assessment186
  Assessment by Monotherapy/Combination Products181
  Assessment by Mechanism of Action191
  Assessment by Route of Administration202
  Assessment by Molecule Type222
Glycoprotein 41 (gp41) Companies Involved in Therapeutics Development2410
  Amunix Operating Inc.241
  BioClonetics Immunotherapeutics, Inc.251
  ConjuChem, LLC261
  Frontier Biotechnologies Co., Ltd271
  InnaVirVax SA281
  Longevity Biotech, Inc291
  Mymetics Corporation301
  Navigen Pharmaceuticals, Inc.311
  Osel, Inc.321
  Pharis Biotec GmbH331
Glycoprotein 41 (gp41) Drug Profiles3425
  Biologic for Infectious Disease Drug Profile342
  CLONE-3 Drug Profile361
  CPT-31 Drug Profile371
  DAC-HIV Drug Profile381
  DS-007 Drug Profile391
  Enfuvirtide-XTEN Drug Profile402
  FB-006M Drug Profile421
  HIV-1 vaccine Drug Profile431
  LBT-5001 Drug Profile441
  Monoclonal Antibodies to Target GP120 and GP41 for HIV Drug Profile451
  MYMV-101 Drug Profile463
  MYMV-201 Drug Profile491
  Recombinant Peptides for HIV-1 Drug Profile501
  Small Molecules to Target GP120 and Gp41 for HIV-1 Infections Drug Profile511
  STOP-3S Drug Profile521
  Synthetic Peptide to Target gp41 for HIV Infection Drug Profile531
  Synthetic Peptides to Inhibit GP120, GP41, Tat, Integrase and Protease for HIV-1 Infection Drug Profile541
  VAC-02 Drug Profile551
  VAC-3S Drug Profile562
  VIR-576 Drug Profile581
Glycoprotein 41 (gp41) Dormant Projects591
Glycoprotein 41 (gp41) Featured News &Press Releases6012
  Sep 19, 2016: Mymetics and Texas Biomedical Research Institute Continue Collaboration on HIV Vaccine Development601
  Jun 06, 2016: Frontier Biotech Long-acting HIV-1 Fusion Inhibitor Albuvirtide Meets 48-Week Primary Objective: Interim Results of a Phase 3 Trial611
  Apr 11, 2016: Mymetics' HIV vaccine candidate confirms promise in preclinical study with Texas Biomed612
  Jul 30, 2015: Encouraging results of the first clinical study of the VAC-3S vaccine against HIV, for which DIAXONHIT develops a companion diagnostic631
  Apr 30, 2015: Texas Biomed receives NIH grant to study papillomavirus-based AIDS vaccine641
  Oct 28, 2014: Amunix and PolyPeptide Enter Into Partnership to Produce XTEN Peptide Conjugates for Evaluation by Third Parties for Pharmaceutical Therapeutics651
  Jul 23, 2014: Amunix and PolyPeptide Publish Multivalent Antiviral XTEN-Peptide Conjugates in vivo Studies in American Chemical Society's Journal "Bioconjugate Chemistry"651
  Dec 01, 2013: InnaVirVax Initiates Phase 2 Clinical Trial Evaluating VAC-3S, A Therapeutic Vaccine Used in Combination With Standard Antiretroviral Therapy in Treatment of HIV-Infection661
  Mar 05, 2013: InnaVirVax Presents Results From Phase I/IIa Clinical Study Of VAC-3S At CROI 2013671
  Feb 21, 2013: Mymetics Announces Publication Of Positive Phase I Study Results Of HIV-1 Vaccine In PLOS ONE671
  Nov 30, 2012: InnaVirVax's HIV Vaccine VAC-3S Achieves Primary End Point In Phase I/IIa Study681
  Jun 18, 2012: InnaVirVax Files New European Patent Application For VAC-3S Immunotherapy691
  Mar 05, 2012: InnaVirVax Initiates Phase I/IIa Clinical Trial Of VAC-3S For Treatment Of HIV Infections691
  Oct 13, 2011: InnaVirVax Obtains Authorization From French Drug Agency To Start Phase I/IIa Study Of VAC-3S701
  Jun 22, 2011: InnaVirVax Announces Positive Preclinical Results Of VAC-3S For Treatment Of HIV Infections711
Appendix722
  Methodology721
  Coverage721
  Secondary Research721
  Primary Research721
  Expert Panel Validation721
  Contact Us721
  Disclaimer731

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Glycoprotein 41 (gp41) - Pipeline Review, H2 2016" Oct 12, 2016. Alacra Store. Nov 15, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Glycoprotein-41-gp41-Pipeline-Review-H2-2016-2088-16802>
  
APA:
Global Markets Direct - Market Research. (2016). Glycoprotein 41 (gp41) - Pipeline Review, H2 2016 Oct 12, 2016. New York, NY: Alacra Store. Retrieved Nov 15, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Glycoprotein-41-gp41-Pipeline-Review-H2-2016-2088-16802>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.